My last question is in relation to that medium term.
Novavax seems to be a medium-term goal, to have domestic manufacturing capacity up and running. We will hopefully have all Canadians vaccinated by then, but there are obviously considerations as it relates to variants; and we should contribute to the global supply as well, because it is obviously a global challenge.
When we look at mRNA technology, at least with the science we have to date, that mRNA technology seems to be better suited to respond to the variants. Who knows? That could change.
We're spending hundreds of billions of dollars on supporting Canadians, individuals and businesses, through this pandemic. Should we not be spending a significant amount to build out mRNA capacity here in Canada?